Kiniksa Pharmaceuticals International (KNSA) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 104.5% versus a loss of 1.1%. Over five years, KNSA leads with a +580.9% price change compared with +66.0% for PTCT. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.07 billion vs $5.22 billion), about 1.2 times the size, while PTC Therapeutics is growing revenue faster (+114.5% vs +60.1%).
On valuation, PTC Therapeutics trades at a lower forward P/E (23.4x vs 48.1x for Kiniksa Pharmaceuticals International). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus 8.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | PTCT |
|---|---|---|
| Share price | $77.75 | $62.53 |
| Market cap | $6.07B | $5.22B |
| 1-day change | -0.28% | -1.11% |
| YTD return | +88.99% | -16.76% |
| 1-year return | +104.51% | -1.06% |
| 5-year return | +580.87% | +66.00% |
| P/E ratio (TTM) | 78.53 | — |
| Forward P/E | 48.06 | 23.36 |
| EPS (TTM) | $0.99 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $1.73B |
| Revenue growth (YoY) | +60.09% | +114.51% |
| Net income (latest FY) | $59.01M | $682.64M |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | 50.09% |
| Net margin | 8.71% | 39.44% |
| 52-week high | $82.94 | $90.87 |
| 52-week low | $35.20 | $61.23 |
| Distance from 52-week high | -6.26% | -31.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +26.05% | +62.79% |
| Average volume | 578.96K | 1.14M |
| Shares outstanding | 48.29M | 83.46M |
| Employees | 366 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed PTCT by 105.6 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus 8.7 cents for Kiniksa Pharmaceuticals International.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +60.09%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
KNSA vs PTCT FAQ
Which is bigger, Kiniksa Pharmaceuticals International or PTC Therapeutics?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.07B compared with $5.22B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, KNSA or PTCT?
KNSA returned +104.51% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Kiniksa Pharmaceuticals International and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.